Brief Summary
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator’s choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronica long-lasting disease that changes slowly over time lymphocytic leukemia (CLL) or small lymphocytic lymphomacancers of the lymphatic system (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Intervention / Treatment
- Drug: BGB-16673
- Drug: Bendamustine
- Drug: Idelalisib
- Drug: Rituximab
- Drug: Venetoclax
Inclusion Criteria:
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imagingtests that create detailed images of areas inside the body (MRI)
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) score 0, 1, or 2
- Adequate liver function
- Adequate bloodthe red bodily fluid that transports oxygen and other nutrients around the body clotting function